Atai Life Sciences raised €38M in a Series B round in Jan 2019. The company is based in Munich, Germany. Investors in the round: Subversive Capital. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
